Rheumatology (Oxford, England) · 2026
Radiographic sacroiliitis progression in psoriatic arthritis.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Carrizo-Abarza Virginia, Mehta Pankti, Kharouf Fadi, Gao Shangyi, Cook Richard J, Gladman Dafna D, Chandran Vinod, Poddubnyy Denis
Аннотация
OBJECTIVE: To assess radiographic sacroiliitis progression in PsA and factors associated with it.
METHODS: We analysed a prospective PsA cohort (1978-2025). Pelvic radiographs were obtained biannually. Change (Δ) in the sacroiliitis sum score (SSS, 0-8; left + right modified New York-mNY-grades) was the primary outcome, while patients with SSS = 8 at baseline were excluded from the analyses. Linear mixed-effects models assessed factors associated with ΔSSS over successive clinic visits. As a secondary outcome, time to incident mNY sacroiliitis was evaluated with Cox regression.
RESULTS: Among 1554 eligible patients (median follow-up 6.00 years), 475/1056 (45%) showed progression in SSS by at least one grade. In univariable analyses, male sex, 66-joint swollen count, PASI, nail disease, syndesmophytes, abnormal ESR/CRP and higher DAPSA were associated with progression, while older age and longer PsA duration were associated with less progression. Biologic/targeted synthetic (b/ts) DMARD exposure and follow-up in the post-2011 era were associated with lower progression rates. In multivariable models, older age and b/tsDMARD exposure retained protective associations. Among 831 patients without definite mNY sacroiliitis at baseline and with ≥1 follow-up radiograph, 189 (22.7%) developed definite mNY sacroiliitis. In univariable Cox analysis, nail disease, higher PASI, abnormal ESR/CRP, higher DAPSA and syndesmophytes were associated with progression, while b/tsDMARD exposure and later eras were associated with lower progression; effects were attenuated after adjustment.
CONCLUSION: Radiographic sacroiliitis progression is common in PsA. Greater inflammatory activity increased risk, whereas b/tsDMARD exposure were protective; progression was lower in the modern treatment era.
METHODS: We analysed a prospective PsA cohort (1978-2025). Pelvic radiographs were obtained biannually. Change (Δ) in the sacroiliitis sum score (SSS, 0-8; left + right modified New York-mNY-grades) was the primary outcome, while patients with SSS = 8 at baseline were excluded from the analyses. Linear mixed-effects models assessed factors associated with ΔSSS over successive clinic visits. As a secondary outcome, time to incident mNY sacroiliitis was evaluated with Cox regression.
RESULTS: Among 1554 eligible patients (median follow-up 6.00 years), 475/1056 (45%) showed progression in SSS by at least one grade. In univariable analyses, male sex, 66-joint swollen count, PASI, nail disease, syndesmophytes, abnormal ESR/CRP and higher DAPSA were associated with progression, while older age and longer PsA duration were associated with less progression. Biologic/targeted synthetic (b/ts) DMARD exposure and follow-up in the post-2011 era were associated with lower progression rates. In multivariable models, older age and b/tsDMARD exposure retained protective associations. Among 831 patients without definite mNY sacroiliitis at baseline and with ≥1 follow-up radiograph, 189 (22.7%) developed definite mNY sacroiliitis. In univariable Cox analysis, nail disease, higher PASI, abnormal ESR/CRP, higher DAPSA and syndesmophytes were associated with progression, while b/tsDMARD exposure and later eras were associated with lower progression; effects were attenuated after adjustment.
CONCLUSION: Radiographic sacroiliitis progression is common in PsA. Greater inflammatory activity increased risk, whereas b/tsDMARD exposure were protective; progression was lower in the modern treatment era.